Combination therapy in multiple myeloma

Share this content:

Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial. A total of 445 patients with multiple myeloma were randomised to lenalidomide plus dexamethasone at either high dose (maximum 480mg) or low dose (maximum 160mg). At one year, overall survival was 96 per cent in the low-dose group, compared with 87 per cent in the high-dose group (p = 0.0002). Just over half of those on the high-dose regimen had grade three or worse toxic effects in the first four months, compared with 35 per cent of patients on the low-dose regimen (p = 0.0001).

Rajkumar SV, Jacobus S, Callander NS et al. Lancet Oncol 2009;doi:10.1016/S1470-2045(09)70284-0

Originally published in the December 2009 edition of MIMS Oncology & Palliative Care.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs